The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung

IJMS, Free Full-Text

Department of Thoracic Oncology National Cancer Center Hospital East

Frontiers Recent progress in targeted therapy for non-small cell

Frontiers Cancer/Testis Antigens as Biomarker and Target for the Diagnosis, Prognosis, and Therapy of Lung Cancer

肺癌靶点研究渐露锋芒，源井生物基因编辑细胞助力肿瘤研究_源井生物

Frontiers Recent progress in targeted therapy for non-small cell

Department of Thoracic Oncology National Cancer Center Hospital East

壹生资讯-它是否能成为肺癌靶向治疗的下一个新靶点？

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates - Sentana-Lledo - Translational Lung Cancer Research

Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions

Frequency of driver mutations in lung adenocarcinoma A. and lung

Phylogenetic analysis and evolution of ALK and LTK a, Phylogenetic